← All indications
Cognition Disorders
Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
Subtype terms (3)
More specific conditions that are subtypes of Cognition Disorders in the MeSH hierarchy.
- Auditory Perceptual Disorders
1 drug approved
- Cognitive Dysfunction
363 drugs (183 approved, 180 experimental)
- Huntington Disease
97 drugs (44 approved, 53 experimental)
Drugs by status
Phase 4 trials (60)
- propofol
- pbr28
- abacavir
- tetracaine
- acetylcysteine
- maraviroc
- alprazolam
- mirabegron
- dabigatran
- blonanserin
- l-alpha-glycerophosphocholine
- ketamine
- cisatracurium
- atenolol
- methylphenidate
- isoflurane
- sevoflurane
- somatropin
- sertraline
- tenofovir
- ritonavir
- warfarin
- lorazepam
- meperidine
- topiramate
- theanine
- lamivudine
- lithium
- olanzapine
- lidocaine
- +30 more
Phase 3 trials (53)
- metformin
- phenylephrine
- dalfampridine
- vitamin d3
- florbetapir
- acetazolamide
- vitamin e
- darbepoetin alfa
- norepinephrine
- exenatide
- butylphthalide
- encenicline
- galantamine
- fluorouracil
- escitalopram
- ziprasidone
- haloperidol
- amlodipine
- calcium
- insulin human
- ephedrine
- leucovorin
- memantine
- nitazoxanide
- pittsburgh compound b
- atorvastatin
- qizhitongluo
- epinephrine
- solanezumab
- 3,4-Methylenedioxymethamphetamine
- +23 more
Phase 2 trials (78)
- melatonin
- florbetaben F-18
- thk-5351
- thalidomide
- oxytocin
- aqw051
- irinotecan
- l-carnosine
- lamotrigine
- edaravone
- alpha-lipoic acid
- cromoglicic acid
- cyclobenzaprine
- prednisone
- ibuprofen
- dimethyl fumarate
- doxorubicin
- droxidopa
- selegiline
- cannabidiol
- fd&c blue #2
- iron succinate
- flutemetamol F-18
- gabapentin
- naltrexone
- probucol
- icosapent ethyl
- soybean oil
- levetiracetam
- vincristine
- +48 more
Phase 1 trials (32)
- ammonia
- angongniuhuang
- mecamylamine
- jnj-39393406
- ketone
- dronabinol
- opc 14117
- papaverine
- phenserine
- nicotine
- slv354
- sobetirome
- Usmarapride
- Samelisant
- tetrahydrocannabinol
- huperzine a
- oxygen
- dextromethorphan
- flortaucipir
- plasmalogen
- mw151
- avl-3288
- 18f-mk6240
- mk 6240
- umbilical cord blood plasma
- dimethyltryptamine
- acd856
- cst-2032
- f-18 3f4ap
- harmine
- +2 more
Other trials (113)
- maltodextrin
- iron
- sucrose
- arachidonic acid
- urea
- beetroot juice
- bifidobacterium animalis
- carbon dioxide
- dark chocolate
- egg
- palmitoylethanolamide
- folic acid
- gelatin
- paclitaxel
- ginseng
- cobalamin
- inulin
- iodine
- whey protein
- leucine
- tryptophan
- vitamin c
- oyster mushroom
- cow milk
- peanut
- ropivacaine
- progestin
- honey
- red blood cells
- remimazolam
- +83 more
Organizations
Organization Involved with Phase 4 Indications (35)
- Novartis
- Sponsor GmbH
- Boehringer Ingelheim
- National Institutes of Health (NIH)
- National Institute of Mental Health (NIMH)
- National Institute on Aging (NIA)
- Central South University
- Allegiance Health
- Chulalongkorn University
- Manhattan Psychiatric Center
- McMaster University
- Monash University
- Nanjing Medical University
- New York University
- Stanford University
- University of Iowa
- University of Toronto
- University of Bern
- Chinese University of Hong Kong
- Columbia University
- Fudan University
- Istanbul University
- University of California, Los Angeles
- University of Copenhagen
- University of Basel
- City University of Hong Kong
- University of Minnesota
- Karolinska Institute
- Instituto de Medicina Integral Professor Fernando Figueira
- Humboldt University
- +5 more
Organization Involved with Phase 3 Indications (21)
- Forest Laboratories
- Roche
- Eli Lilly
- Materia Medica Holding
- Oregon Health and Science University
- University of Heidelberg
- University of Parma
- University of Southern California
- Yale University
- University of Amsterdam
- Free University of Amsterdam
- European Organisation for Research and Treatment of Cancer
- Brain & Behavior Research Foundation
- Alzheimer's Therapeutic Research Institute
- Lundbeck
- Donaghue Foundation
- Johnson and Johnson
- University of Caen-Normandie
- Government of France
- University of Picardie Jules Verne
- The University of Texas, Dallas
Organization Involved with Phase 2 Indications (27)
- AbbVie
- Cephalon
- Pfizer
- Cognition Therapeutics
- The Dana Foundation
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute on Drug Abuse (NIDA)
- University of Pittsburgh
- Johns Hopkins University
- Russian Academy of Medical Sciences
- University of Ottawa
- University of Rochester
- Wake Forest University
- Vanderbilt University
- Icahn School of Medicine at Mount Sinai
- BASF
- Rush University
- Scripps
- State University of New York, Buffalo
- The Florey Institute of Neuroscience and Mental Health
- Neurologic AIDS Research Consortium
- Institut Hospital del Mar d'Investigacions Mèdiques
- NeuroActiva
- Oslo Metropolitan University
- Pre Diagnostics AS
Organization Involved with Phase 1 Indications (16)
- Abbott
- Avid Radiopharmaceuticals
- GlaxoSmithKline
- Suven Life Sciences Limited
- Agentschap NL
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- University of Pennsylvania
- Harvard University
- University of Maryland
- University of Zagreb
- Tel Aviv University
- Pharmaceutical Research Associates, Inc. (PRA)
- Janssen Pharmaceutica NV
- Alzheimer's Association
- IQVIA
- Klinički Bolnički Centar Zagreb
Organization Involved with Other Experimental Indications (14)